证券代码：688337 证券简称：普源精电 公告编号：2025-031 普源精电科技股份有限公司 7 号——回购股份》的相关规定，公司在回购期间，应当在每个月的前 3 个交易 日内公告截至上月末的回购进展情况。现将回购股份的进展情况公告如下： 截至 2025 年 6 月 30 日，公司尚未实施股份回购。 重要内容提示： | 回购方案首次披露日 | 2025/4/30 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 回购方案实施期限 | 年 日~2026 2025 4 | 4 | 月 | 29 | 年 | 月 | 28 | 日 | | 预计回购金额 | 3,000万元~5,000万元 | | | | | | | | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | | | | | | | | □用于转换公司可转债 □为维护公司价值及股东权益 | | | | | | | | | 累计已回购股数 | 0万股 | | | | | | | | | 累计已回购股数占总股本比例 | 0% | | | ...

瑞财经 严明会 6月25日，镁伽科技有限公司(以下简称：镁伽科技)向港交所主板提交上市申请，摩根士 丹利、华泰国际、德意志银行和建银国际为其联席保荐人。 据招股书，镁伽科技成立于2016年，是中国机器人技术应用领域领先的自主智能体提供商，药明康德、 中金资本、Joy Capital参与投资。 镁伽科技是国家级专精特新"小巨人"企业。被《麻省理工科技评论》评为"50家最聪明的公司"之一。根 据灼识谘询的资料，按2024年智慧实验室的收入计算，镁伽科技位居中国国内自主智能体供应商首位。 黃瑜清、乔志新、张琰、于春涛及丁新宇通过其受控实体(即Nularis Ventures Ltd.、Vizionix Capital Ltd.、Marvortex Ventures Ltd.、Vernal Ventures Ltd.、HuiHorizon Group Ltd.及Mechnologix Limited)为单 一最大股东集团，合共持有公司已发行股本约16.08%。 黄瑜清，39岁，创始人、主席、执行董事、首席执行官。 乔志新，46岁，联合创始人、执行董事、 高级副总裁、首席运营官。 张琰，42岁，联合创始人、执行董事、高 ...

Core Insights - The article analyzes the salary situation of R&D and sales employees in 50 listed instrument companies in China, highlighting the competitive landscape for talent in the industry [2][3]. R&D Salary Analysis - The average annual salary for R&D personnel in listed instrument companies for 2024 is 232,900 yuan, reflecting a slight increase of 2.64% compared to 2023, indicating a growing emphasis on R&D talent [3]. - There is a significant disparity in R&D salaries among companies, with Mindray Medical leading at 505,100 yuan per year, followed by Puyuan Precision, Meiya Optoelectronics, and others, while some companies offer as low as 100,000 yuan per year [3][5]. - The salary gap may lead to a concentration of R&D talent in top companies, exacerbating the competitive imbalance in the industry [4]. Sales Salary Analysis - The average annual salary for sales personnel in 2024 is 334,000 yuan, showing a growth of 3.66% from the previous year, indicating an increasing reliance on sales teams in a competitive market [9]. - Mindray Medical, Meiya Optoelectronics, and others top the sales salary rankings, with Mindray's sales personnel earning 729,600 yuan per year, reflecting the high value placed on sales talent [9][11]. - The high salary levels in the sales sector are attributed to the technical complexity and high price of instrument products, necessitating skilled sales personnel [10]. Salary Rankings and Implications - The article provides detailed rankings of R&D and sales salaries, showcasing the top 30 companies in each category, which serves as a reflection of the industry's current state [5][11]. - High salaries are often associated with strong performance in technology innovation and market expansion, while lower salaries may lead to talent loss and reduced innovation capacity [14]. - For job seekers, the salary rankings serve as a reference point, emphasizing the importance of considering a company's growth potential and culture alongside salary [14]. Future Outlook - The importance of R&D and sales talent is expected to grow as the instrument industry continues to develop, highlighting the need for companies to attract and nurture talent through competitive compensation and supportive work environments [15].

Investment Rating - The investment rating for the company is "Outperform" (maintained) [1] Core Views - The company has signed a cooperation agreement with Xi'an University of Electronic Science and Technology to promote its high-end strategy, focusing on deep integration of industry, academia, and research [6] - The company is committed to high-end product development and has seen significant sales growth in its DS80000 series high-end digital oscilloscopes, with strong demand from strategic customers [6] - The electronic measurement instrument industry is expected to continue steady growth, with domestic companies accelerating their technological advancements and narrowing the gap with overseas competitors [6] Financial Data and Profit Forecast - Total revenue is projected to grow from 776 million in 2024 to 1,332 million by 2027, with a compound annual growth rate (CAGR) of approximately 18.2% [5][8] - The net profit attributable to the parent company is expected to increase from 92 million in 2024 to 262 million by 2027, reflecting a significant growth trajectory [5][8] - The company's gross margin is forecasted to improve from 59.1% in 2024 to 62.7% in 2027, indicating enhanced profitability [5]

证券代码：688337 证券简称：普源精电 公告编号：2025-030 普源精电科技股份有限公司 2024年年度股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 6 月 25 日 （二） 股东大会召开的地点：公司会议室（苏州市高新区科灵路 8 号） （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的优先股股东及 其持有表决权数量的情况： | 1、出席会议的股东和代理人人数 | 107 | | --- | --- | | 普通股股东人数 | 107 | | 2、出席会议的股东所持有的表决权数量 | 135,888,826 | | 普通股股东所持有表决权数量 | 135,888,826 | | 3、出席会议的股东所持有表决权数量占公司表决权数量的比 | 70.1353 | | 例（%） | | | 普通股股东所持有表决权数量占公司表决权数量的比例（%） | 70.1353 | （四） 表决方式 ...

上海市石门一路 288 号 兴业太古汇香港兴业中心一座 26 层 邮编：200041 电话：（86-21）5298 5488 传真：（86-21）5298 5492 junhesh@junhe.com 2024 年年度股东大会的法律意见书 致：普源精电科技股份有限公司 君合律师事务所上海分所（以下简称"本所"）接受普源精电科技股份有限 公司（以下简称"公司"）的委托，根据《中华人民共和国公司法》（以下简称 "《公司法》"）、《中华人民共和国证券法》、中国证券监督管理委员会颁布实施 的《上市公司股东会规则》（以下简称"《股东会规则》"）等中国现行法律、行政 法规和规范性文件（以下简称"中国法律、法规"，为本法律意见书法律适用之 目的，不包括中国香港特别行政区、中国澳门特别行政区及台湾地区法律、法规） 以及《普源精电科技股份有限公司章程》（以下简称"《公司章程》"）的有关规定， 就公司 2024 年年度股东大会（以下简称"本次股东大会"）有关事宜出具本法 律意见书。 本法律意见书仅就本次股东大会的召集和召开程序、出席本次股东大会人员 的资格、召集人资格、会议表决程序是否符合中国法律、法规及《公司章程》的 规定以及 ...

Investment Rating - The report maintains an "Outperform the Market" rating for the mechanical equipment industry [4][30]. Core Views - The humanoid robot sector is highlighted for its growth potential, with a focus on key suppliers and companies with strong market positions. Specific components such as joint modules, dexterous hands, and reducers are identified as critical areas for investment [2][3]. - AI infrastructure is expected to see continued capital expenditure growth driven by demand for data centers, benefiting companies involved in gas turbines and chillers [2]. - The low-altitude economy is progressing rapidly, with a national low-altitude traffic project initiated to standardize air traffic management [3]. - The smart welding robot market is projected to grow significantly, particularly in the steel structure industry, with a market potential nearing 100 billion [3]. - 3D printing technology is gaining traction in various sectors, including aerospace and consumer electronics, due to its advantages in creating complex structures and reducing development cycles [3]. - X-ray detection equipment is experiencing rapid growth driven by demand in healthcare and industrial sectors, with a focus on domestic production of core components [3]. Summary by Sections Industry Dynamics - Recent developments include the introduction of various humanoid robots and AI infrastructure projects, such as the opening of a new data center by Alibaba Cloud in South Korea [1][19]. - The report notes significant growth in 3D printing equipment production, with a year-on-year increase of 40% in May [20]. Government News - The China Securities Regulatory Commission supports the application of the fifth set of listing standards for companies in cutting-edge technology sectors, including AI and low-altitude economy [21]. Company Developments - Notable partnerships and investments include Demar Technology's strategic agreement with Zhiyuan Robotics and Qinan Co., Ltd.'s investment in Moxian Technology [23][24]. - Midea's humanoid robot has successfully begun operations in its factories, marking a significant step in automation [16]. - The launch of the Star Motion Q5 intelligent robot showcases advancements in flexible joint technology and AI control systems [18]. Key Company Earnings Forecast and Valuation - Several companies are rated as "Outperform the Market," including Green's Harmonics, Huichuan Technology, and Zhaowei Electric, with projected earnings per share (EPS) growth for 2024 and 2025 [7][28].

Group 1: Core Insights - The "Science and Technology Innovation Board Eight Articles" has significantly enhanced the inclusivity and support for high-quality, unprofitable technology enterprises in the capital market [2][6][3] - Companies like Tianyue Advanced and Baile Tianheng have successfully leveraged the policies to achieve rapid growth and innovation in their respective fields, such as silicon carbide substrates and innovative cancer therapies [1][2][3] - The implementation of the "Eight Articles" has led to successful mergers and acquisitions, exemplified by Puyuan Precision's acquisition of Nais Electronics, marking a significant milestone in the electronic measurement instrument industry [2][18] Group 2: Company Developments - Tianyue Advanced has become the first company globally to industrialize 2-inch to 8-inch silicon carbide substrates and plans to launch the world's first 12-inch silicon carbide substrate in November 2024 [1] - Baile Tianheng's new antibody-drug conjugate (ADC) has set a record for domestic innovative drug licensing, and the company has achieved a market capitalization exceeding 100 billion yuan, becoming the third innovative drug company in A-shares to reach this milestone [1][2] - China Communications Signal has successfully issued science and technology bonds in just 35 working days, showcasing the efficiency of the new financing tools [2][8] Group 3: Future Expectations - Companies express a strong desire for further improvements in the capital market, including more active trading on the Science and Technology Innovation Board and better support for long-term investments in "hard technology" [3][7][14] - There is a collective anticipation for the continued evolution of policies that will enhance the ability of companies to engage in mergers and acquisitions, thereby strengthening their competitive positions [2][15][17] - The focus on "hard technology" and the commitment to innovation are seen as critical for the future success of companies listed on the Science and Technology Innovation Board [7][14][17]

Investment Rating - The report emphasizes the importance of self-reliance in key technology sectors, indicating a positive outlook for investment in industries aligned with national strategic needs [3][9][18]. Core Insights - The report outlines a framework for self-reliant industry research, highlighting the need for China to overcome "bottleneck" issues in various sectors due to ongoing geopolitical tensions [9][18][21]. - It identifies several key sectors such as electronics, computing, metals, communications, machinery, military, pharmaceuticals, and chemicals as critical areas for investment and development [10][12][21]. Summary by Relevant Sections Strategy: Constructing a Self-Reliant Research Framework - The report establishes a multi-dimensional evaluation system to identify beneficiary industries and key stocks, focusing on both industry-level and individual stock-level analyses [10][31][36]. Electronics - The demand for core processors like GPU, CPU, and NPU is increasing, with significant investment opportunities in semiconductor manufacturing and packaging due to external technological restrictions [10][12]. Computing - The computing sector is experiencing growth driven by AI applications, with a broad market potential for domestic products as the industry transitions from usable to highly functional [10][12]. Metals - The military sector's focus on domestic production of titanium and high-temperature alloys is highlighted, with expectations for rapid growth in these materials due to increasing demand [11][12]. Communications - The strategic importance of satellite internet has been underscored, particularly in light of recent geopolitical events, indicating a significant opportunity for development in this area [11][12]. Machinery - The report notes a substantial market space for high-end equipment, with a low current domestic production rate, suggesting significant potential for domestic replacements [11][12]. Military - The global commercial aerospace engine market is projected to exceed 650 billion annually, with China expected to capture a significant share, emphasizing the need for independent development in this sector [11][12]. Pharmaceuticals - The life sciences sector is identified as a key area for domestic innovation, particularly in medical instruments and consumables, driven by supply chain security concerns [12][21]. Chemicals - The report highlights the urgency for domestic alternatives in certain chemical sub-industries, particularly in semiconductor materials, due to high technical barriers and low current domestic production rates [12][21].

Group 1 - The company announced a share repurchase plan with a total expected amount between RMB 30 million and RMB 50 million [1] - The repurchase period is set from April 29, 2025, to April 28, 2026 [1] - The repurchased shares will be used for employee stock ownership plans or equity incentives [1] Group 2 - As of May 31, 2025, the company has not yet implemented any share repurchases [2] - The company will adhere to relevant regulations and make repurchase decisions based on market conditions [2] - The company commits to timely information disclosure regarding the progress of the share repurchase [2]